- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02681653
Study the Impact of Statins in Septic Shock
Prospective Randomized Study to Assess Impact of Statins in Septic Shock
Sepsis is a common, expensive, frequently fatal and highly complex inflammatory syndrome wherein multiple cellular and humoral pathways are involved. Since it's a multifactorial syndrome merely blocking one of the various inflammatory pathways may not suffice to provide effective treatment and this may partly explain why most of the adjunctive therapies developed for severe sepsis have yielded disappointing results in rigorous clinical trials. Statins have varied pleiotropic effects on the inflammatory mediators and there addition to the current adjuvant therapies in septic shock may help in reduction of mortality. The present trial aims to study survival benefit and changes in bio-marker levels in septic shock.
Adult patients (>=18 years) in septic shock and admitted to ICU will be included in the study. Patients will be randomized as per computer generated random number into the Drug (Atorvastatin, 40 mg) or matched placebo group. Drug or placebo will be given to selected patient via nasogastric tube for 7 days. Bio markers (Il-6, TNF-alpha) estimated during the trial week (Days 1, 4, and 7). All clinical and study personnel and patients remained blinded to the study group assignment throughout the trial.
Study Overview
Detailed Description
Objectives:
- Study impact of statins on levels of biomarkers (IL-6 and TNF-α) of sepsis.
- Study survival benefit of statins in septic shock.
Introduction:
Sepsis is the leading cause of mortality in non-coronary ICUs. Mortality associated with sepsis is still considerably high. Rising economic burden of managing sepsis is a major concern. Statin is an anti-hyperlipidemic drug with pleiotropic effects. It has properties like anti-inflammatory/oxidative, immunomodulatory effects, enhances endothelial function, reduction in blood thrombogenicity, and increased nitric oxide (NO) bioavailability. Available evidence suggests that statins may play a positive role in reduction of mortality in sepsis. However, the multidimensional heterogeneous character of the available studies does not allow drawing firm conclusions about its usefulness in sepsis and septic shock. This randomized, double blinded, placebo controlled trial is an attempt to study the impact of statins on mortality and biomarker levels in septic shock.
Details of material and methods:
Patients >= age 18 yrs meeting the American European consensus conference definition of septic shock will be enrolled into the study. After the written informed consent from the primary decision maker the patients will be randomized into either the drug or placebo group. Each group will either receive Atorvastatin 40mg or a matched placebo for 7 days. IL-6 and TNF alpha levels will be estimated on D1, D4 and D7 of the trial week. Relevant clinical and laboratory (clinical biochemistry, hematological, coagulation parameters, LFT and renal function tests) will be recorded simultaneously. Severity scores, event free days (vasopressor, ventilation, dialysis, transfusion, parenteral nutrition), and mortality after 28 days of inclusion in study will be recorded.
Ethical Issues:
Written informed consent will be taken from either the patient (if possible) or from the primary decision maker related to the patient.
Study population:
A total of 80 patients of septic shock admitted in ICU will be enrolled into this study. Patients either admitted with septic shock or who develop septic shock during their stay in ICU will be eligible for inclusion into the study. The statin and placebo group will have 40 patients each.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
UP
-
Lucknow, UP, India, 226014
- Department of Immunology, SGPGIMS
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, India, 226014
- Department of Critical Care Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical disease of septic shock
- Aged eighteen years and above
- Admitted to ICU
Exclusion Criteria:
- Previous statin induced myopathy or hypersensitivity reaction
- Greater than two and half times elevated liver transaminases
- Chronic liver disease
- Pregnant or lactating mothers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Statin
Atorvastatin, 40 mg for 7 days in patients of septic shock admitted to ICU
|
Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
|
PLACEBO_COMPARATOR: Placebo
Matched placebo, 40 mg for 7 days in patients of septic shock admitted to ICU
|
Equally matched placebo for 7 days to patients of septic shock admitted to ICU
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: 28 day of ICU stay
|
28 day mortality after inclusion in study.
|
28 day of ICU stay
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cytokines in septic shock
Time Frame: Day 1, 4 and 7 of commencement of trial drug.
|
IL-6, TNF-α levels on Day 1, 4 and 7.
|
Day 1, 4 and 7 of commencement of trial drug.
|
Vasopressor free days.
Time Frame: 28 days after commencement of trial drug.
|
Vasopressor free days during septic shock.
|
28 days after commencement of trial drug.
|
Ventilation free days.
Time Frame: 28 days after commencement of trial drug.
|
Ventilation free days during septic shock.
|
28 days after commencement of trial drug.
|
Renal replacement free days.
Time Frame: 28 days after commencement of trial drug.
|
Renal replacement free days during septic shock.
|
28 days after commencement of trial drug.
|
Transfusion free days.
Time Frame: 28 days after commencement of trial drug.
|
Transfusion free days during septic shock.
|
28 days after commencement of trial drug.
|
Total parenteral nutrition free days.
Time Frame: 28 days after commencement of trial drug.
|
Total parenteral nutrition free days during septic shock.
|
28 days after commencement of trial drug.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ratender K Singh, MD., Sanjay Gandhi Post Graduate Institute of Medical Sciences
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Systemic Inflammatory Response Syndrome
- Inflammation
- Sepsis
- Shock, Septic
- Shock
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Atorvastatin
Other Study ID Numbers
- PGI/IMP/IEC/56/19.08.2011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Septic Shock
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, BonnUnknownSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockGermany
-
University Medicine GreifswaldUnknownSepsis Septic ShockGermany
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated...Recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedSeptic Shock HyperdynamicFrance
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
National Taiwan University HospitalBaxter Healthcare CorporationRecruiting
-
Charite University, Berlin, GermanyCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
Mansoura UniversityUnknown
-
University of ZurichCompletedPatients in Septic ShockSwitzerland
Clinical Trials on Atorvastatin
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
-
Organon and CoCompleted
-
Obafemi Awolowo University Teaching HospitalOpen PhilanthropyRecruitingTuberculosis | Pulmonary Tuberculosis | Koch's DiseaseNigeria
-
Hippocration General HospitalCompletedCoronary Artery Disease | Atherosclerosis | Endothelial Dysfunction | Oxidative Stress | HMG-CoA Reductase Inhibitor ToxicityGreece
-
PfizerCompletedHypertriglyceridemia | Hyperlipoproteinemia Type IVUnited States, Canada
-
Organon and CoCompleted
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Unknown
-
St. Olavs HospitalUllevaal University Hospital; Oslo University Hospital; University Hospital of... and other collaboratorsNot yet recruiting
-
Zhongda HospitalNot yet recruitingAcute Ischemic Stroke | Mechanical ThrombectomyChina